Thursday, October 12, 2017

The Liver Meeting 2017: Progress in Fatty Liver and Pediatric Liver Disease

Conference Coverage from
The Liver Meeting 2017: American Association for the Study of Liver Diseases (AASLD)

Progress in Fatty Liver and Pediatric Liver Disease
Damian McNamara
October 11, 2017

WASHINGTON, DC — Advances in the treatment of nonalcoholic steatohepatitis (NASH) — including results from a phase 2 trial of a liver-targeted selective inhibitor of acetyl-CoA carboxylase — will be in the spotlight here at The Liver Meeting 2017: American Association for the Study of Liver Diseases (AASLD).

Link
The Liver Meeting
Abstract supplement for The Liver Meeting® 2017
Oral Abstracts and Posters

No comments:

Post a Comment